For all the hype, psychedelics such as MDMA or psilocybin won’t succeed as a treatment or service line without substantial clinical support within behavioral health organizations. As recent ketamine-provider stumbles demonstrate, simply establishing access to and attempting to scale singular forms of treatment tend to lead to failure. Further, such treatment-specific ventures fail to address […]
Fluence
Ketamine therapy has a long way to go before it becomes a major part of the behavioral health industry. The high-profile stumbles at Field Trip Health & Wellness and Ketamine Wellness Center highlight the fraught environment the half-a-century-old drug faces in treating mental health at scale. It also illustrates the risk of moving too early […]